Literature DB >> 6708184

The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report.

C B Brendler, J T Isaacs, A L Follansbee, P C Walsh.   

Abstract

We are attempting to develop a method to predict hormonal response in patients with carcinoma of the prostate. We have measured multiple biochemical variables and determined Gleason grade in prostatic needle biopsies obtained from 16 patients immediately before castration or initiation of estrogen therapy. Biochemical variables included 6 enzymes (3 enzymes involved in androgen metabolism and 3 hydrolytic enzymes), androgen receptor content, and tissue testosterone and dihydrotestosterone content. The 16 patients were followed prospectively and the response of each patient to hormonal therapy was assessed clinically. Two groups of patients were identified: 1 group of 7 patients in which the mean duration of response was 7.7 plus or minus 1.5 months (plus or minus standard error) and in which all patients have relapsed and died of their disease, and a second group of 9 patients in which the mean duration of response was 18.6 plus or minus 1.6 months (plus or minus standard error) and in which 7 of the 9 patients (78 per cent) are still responding. The 2 groups were statistically different (p less than 0.001) in terms of duration of response. The 2 groups could not be distinguished by Gleason grade, single enzymatic activities or tissue androgen content. The mean value of nuclear salt extractable androgen receptor was statistically different between the 2 groups (p less than 0.05) but with considerable overlap of individual patients between the 2 groups. An index was developed based on multiple enzymatic activities, which separated the 2 response groups better than any single variable alone (p less than 0.02). When salt extractable nuclear androgen receptor was included in the numerator of this index the 2 groups were separated almost completely. This preliminary study suggests that the measurement of multiple biochemical variables may be useful in predicting hormonal response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708184     DOI: 10.1016/s0022-5347(17)50585-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.

Authors:  H Fuse; I Mizuno; T Yokoyama; M Sakamoto; T Katayama
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 2.  Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.

Authors:  Petros D Grivas; Diane M Robins; Maha Hussain
Journal:  Crit Rev Oncol Hematol       Date:  2012-06-16       Impact factor: 6.312

3.  Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate.

Authors:  L Castagnetta; G Carruba; E Fecarotta; M Lo Casto; R Cusimano; M Pavone-Macaluso
Journal:  Urol Res       Date:  1992

Review 4.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

5.  Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient.

Authors:  J P Elo; P Härkönen; A P Kyllönen; O Lukkarinen; P Vihko
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.